36 results about "Thyrotropin receptor" patented technology

A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.

This invention describes monoclonal antibodies that suppress thyrotropin receptor constitutive activity and methods of using the antibodies to treat thyroid related diseases; particularly hyperthyroidism and thyroid cancer

The invention relates to the technical field of in-vitro diagnosis, in particular to a kit for detecting the concentration of a stimulating thyrotrophin receptor antibody. The kit comprises magnetic particles coated with a stimulating thyrotrophin receptor antibody, a stimulating thyrotrophin receptor containing a marker label, and a stimulating thyrotrophin receptor antibody calibration product.According to the invention, the stimulating thyrotrophin receptor is used for constructing a stimulating thyrotrophin receptor antibody kit for the first time and the stimulating thyrotrophin receptoris only bound with the stimulating thyrotrophin receptor antibody, thereby eliminating the influence on the measuring system by the inhibiting thyrotrophin receptor antibody and the neutral thyrotrophin receptor antibody. The construction of the kit detection method is based on the high-sensitivity chemiluminiscence determination technology and the high-specificity immune reaction is combined; and thus the method has advantages of high sensitivity, high specificity and wide detection range.

The present invention provides a peptide at least partially derivable from human Thyroid Stimulating Hormone Receptor (TSHR) which peptide is capable of binding to an MHC molecule in vitro and being presented to a T cell without further antigen processing. The present invention also relates to the use of such peptides for the prevention or suppression of activating autoantibody formation in Graves' Disease.

This invention describes monoclonal antibodies that suppress thyrotropin receptor constitutive activity and methods of using the antibodies to treat thyroid related diseases; particularly hyperthyroidism and thyroid cancer.

The present invention provides a composition which comprises the following Thyroid Stimulating Hormone Receptor (TSHR) peptides: (i) all or part of the amino acid sequence KKKKYVSIDVTLQQLESHKKK (SEQ ID NO: 1), or a part thereof, or a sequence having at least 60% sequence identity to SEQ ID NO:1; and (ii) all or part of the amino acid sequence GLKMFPDLTKVYSTD (SEQ ID NO: 2), or a part thereof, or a sequence having at least 60% sequence identity to SEQ ID NO:2. The present invention also relates to the use of such a composition for the prevention or suppression of activating autoantibody formation in Graves' disease.

The invention provides an isolated antibody for the TSHR which is an antagonist of TSH. The invention also relates to methods of using antibodies of the invention.

The invention discloses the expressing product of human thyrotropin receptor extracellular domain amino terminus gene and its preparation methods and the application of the product in the enzyme immunoassay technology. The purpose of this invention is to divide TSHR-ecd cDNA into three regions(hTSHR-N terminal, hTSHR-C terminal and hTSHR-M terminal), clone them respectively, especially the hTSHR-Nterminal, construct expression vector, express in E.coli, and establish TRAb (including TSAb. TSBAb) ELISA technology taking the protein of this gene engineering fragmentas antigen. The said invention develops novel channel for further research of TSHR antigen determinant and settles foundation for the ultimate transformation into TSAb, TSBAb clinical diagnostic kit.

A binding partner for the TSH receptor, which binding partner comprises, or is derived from, a human monoclonal or recombinant antibody, or one or more fragments thereof, reactive with the TSH receptor, uses thereof, methods of diagnosis and therapy employing the same, and anti-idiotypic antibodies thereto.

Disclosed are a fusion protein comprising a thyrotropin receptor (TSHR) fragment and the use thereof. More specifically, disclosed are a fusion protein comprising a TSHR fragment comprising an extracellular domain of a wild-type TSHR and having a substitution of an amino acid at specific position and an immunoglobulin Fc region or a carboxy-terminal cap (C-CAP), and the use thereof. The fusion protein has improved pharmaceutical efficacy, in-vivo persistence and protein stability and a pharmaceutical composition containing the fusion protein as an active ingredient is useful as a therapeutic agent or diagnostic reagent for the alleviation of Graves' disease and Graves' ophthalmopathy.

TSHR agonists that are substantially desialylated are described for treating metabolic syndrome and obesity and for inducing lipolysis. The TSHR polypeptide agonists are useful for treatment of hallmarks of metabolic syndrome: obesity, insulin resistance, hyperlipidemia, and liver steatosis, without producing a hyperthyroid state in treated individuals.

The invention provides an isolated antibody for the TSHR which is an antagonist of TSH. The invention also relates to methods of using antibodies of the invention.

The invention discloses a kit for detecting gene mutational sites of a TSHR (thyroid stimulating hormone receptor), and a use method and application thereof. The kit comprises 1) fluorescence PCR detection mixed liquid, 2) Taq enzyme, 3) a TSHR wild type positive comparison product, 4) a TSHR mutation type positive comparison product, and 5) ddH2O. The kit detects coding genes of 623 sites and / or631 sites of TSHR proteins by adopting a fluorescence quantitative PCR method, and judges whether the coding genes are mutated or not so as to judge whether the 623 sites and / or 631 sites of the TSHR proteins are mutated or not. The mutation of the protein sites can be used for aided diagnosis and prevention of thyroid diseases. The kit has the characteristics of real-time detection, quantitative and high-throughput detection and the like, is easy to operate, and has high sensitivity and high specificity.

Dual suppression of the MAP kinase and PI3K / Akt pathways showed synergistic or greatly enhanced anti-melanoma cell effects, compared to suppression of a single pathway, including the inhibition of cell proliferation, transformation and invasion, induction of G0 / G1 cell cycle arrest and, importantly, cell apoptosis. Remarkably, suppression of either pathway induces the expression of thyroid iodide-handling genes and dual suppression of the two pathways synergistically and robustly induces expression of these genes, accompanied by uptake of radioiodine in the cells. These genes include sodium / iodide symporter, thyroid-stimulating hormone receptor, thyroglobulin, thyroperoxidase, pendrin gene, thyroid transcription factors (e.g., TTF-1, TTF-2, PAX8) and other thyroid genes. Targeting major signaling pathways, such as the MAP kinase and PI3K / Akt pathways, for potent cell death, optionally coupled with induction of thyroid gene expression for adjunct radioiodine ablation therapy may be used for many human cancers, both thyroid and non-thyroid.

The present invention relates to a cyclic peptide, its use in the treatment, amelioration or prevention of a disease caused by antibodies targeting the thyrotropin-TSH receptor (TSHR) in the thyroid gland, in particular Graves' disease and orbitopathy, and to pharmaceutical compositions comprising the same.

The invention discloses a method for constructing an animal model of thyroid-associated eye disease induced by gene immunity and application of rapamycin drugs. The construction method is as follows: 1) Dilute the stock solution of adenovirus expressing human thyroid-stimulating hormone receptor with PBS at a volume ratio of 1:50 to obtain Ad-TSHR dilution; 2) On the first day of the 0th week, give the experimental The left and right gluteus maximus of the animal were injected with 25uL Ad-TSHR dilution respectively; 3) the operation of step 2) was repeated in the 3rd, 6th, 10th, 14th, 18th, 22nd, 26th, and 30th weeks until the experimental animals were induced to produce Thyroid-associated eye disease, that is, the successful construction of an animal model of thyroid-associated eye disease induced by gene immunity. The invention fills up the gap in the field of thyroid-associated eye disease models, and is also a new exploration of rapamycin for the treatment of thyroid-associated eye diseases.